Belite Bio to Participate in Three Upcoming Investor Conferences
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company specializing in novel therapeutics for degenerative retinal diseases, has announced its participation in three major investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (September 5, 8:00 am ET), the Morgan Stanley 23rd Annual Global Healthcare Conference (September 8, 5:35 pm ET), and the H.C. Wainwright 27th Annual Global Investment Conference (September 9, 8:00 am ET). All presentations will be available via webcast on the company's investor relations website, with replays archived for 90 days.
Belite Bio (NASDAQ: BLTE), azienda in fase clinica dedicata allo sviluppo di nuovi farmaci per le malattie degenerative della retina, ha annunciato la propria partecipazione a tre importanti conferenze per investitori nel settembre 2025.
La società terrà presentazioni al Cantor Global Healthcare Conference (5 settembre, ore 8:00 ET), al Morgan Stanley 23rd Annual Global Healthcare Conference (8 settembre, ore 17:35 ET) e al H.C. Wainwright 27th Annual Global Investment Conference (9 settembre, ore 8:00 ET). Tutti gli interventi saranno trasmessi in webcast sul sito investor relations della società, con le registrazioni disponibili in archivio per 90 giorni.
Belite Bio (NASDAQ: BLTE), una compañía en fase clínica especializada en el desarrollo de terapias novedosas para enfermedades degenerativas de la retina, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025.
La empresa presentará en la Cantor Global Healthcare Conference (5 de septiembre, 8:00 am ET), en la Morgan Stanley 23rd Annual Global Healthcare Conference (8 de septiembre, 5:35 pm ET) y en la H.C. Wainwright 27th Annual Global Investment Conference (9 de septiembre, 8:00 am ET). Todas las presentaciones estarán disponibles por webcast en la web de relaciones con inversores de la compañía, con las repeticiones archivadas durante 90 días.
Belite Bio (NASDAQ: BLTE)는 망막 퇴행성 질환을 위한 혁신 치료제 개발을 전문으로 하는 임상 단계 제약사로, 2025년 9월에 열리는 주요 투자자 콘퍼런스 세 곳에 참가한다고 발표했습니다.
회사는 Cantor Global Healthcare Conference(9월 5일, 오전 8:00 ET), Morgan Stanley 23rd Annual Global Healthcare Conference(9월 8일, 오후 5:35 ET), H.C. Wainwright 27th Annual Global Investment Conference(9월 9일, 오전 8:00 ET)에서 발표를 진행합니다. 모든 발표는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있으며, 재방송은 90일 동안 아카이브됩니다.
Belite Bio (NASDAQ: BLTE), une société en phase clinique spécialisée dans le développement de nouvelles thérapies pour les maladies dégénératives de la rétine, a annoncé sa participation à trois grandes conférences investisseurs en septembre 2025.
La société présentera lors de la Cantor Global Healthcare Conference (5 septembre, 8h00 ET), de la Morgan Stanley 23rd Annual Global Healthcare Conference (8 septembre, 17h35 ET) et de la H.C. Wainwright 27th Annual Global Investment Conference (9 septembre, 8h00 ET). Toutes les présentations seront diffusées en webcast sur le site relations investisseurs de la société, les replays étant archivés pendant 90 jours.
Belite Bio (NASDAQ: BLTE), ein Unternehmen in der klinischen Entwicklungsphase, das sich auf neuartige Therapeutika für degenerative Netzhauterkrankungen spezialisiert hat, gab seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 bekannt.
Das Unternehmen wird auf der Cantor Global Healthcare Conference (5. September, 08:00 Uhr ET), der Morgan Stanley 23rd Annual Global Healthcare Conference (8. September, 17:35 Uhr ET) und der H.C. Wainwright 27th Annual Global Investment Conference (9. September, 08:00 Uhr ET) präsent sein. Alle Präsentationen werden per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, Wiedergaben werden für 90 Tage archiviert.
- None.
- None.
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details of the presentations are as follows:
- Cantor Global Healthcare Conference
- September 5, 2025, at 8:00 am ET, fireside chat
- Morgan Stanley 23rd Annual Global Healthcare Conference
- September 8, 2025, at 5:35 pm ET, fireside chat
- H.C. Wainwright 27th Annual Global Investment Conference
- September 9, 2025, at 8:00 am ET, fireside chat
Webcast Link Instructions
A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) presenting at the Cantor Global Healthcare Conference 2025?
What time is Belite Bio's presentation at the Morgan Stanley Healthcare Conference 2025?
How can investors access Belite Bio's conference presentations?
What is Belite Bio's main business focus?
